Lupus Research Alliance News
Saluting Women Shaping LRA’s Strategic Scientific Direction

March 8, 2022 In honor of Women’s History Month, the LRA is saluting the three exceptional women who serve on our Scientific Advisory Board. Each is a stand-out in lupus research discovery: Mary Collins, PhD, Instructor at Harvard Medical School;  Judith James, MD, PhD, Chair of the Arthritis and Clinical Immunology Program and Lou Kerr […] READ MORE

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] READ MORE

Catch Up on LRA News with Lupus Research Update Vol. 1, 2022

February 17, 2022 It’s with great pride that I share a sampling of the many extraordinary accomplishments of last year in our first Lupus Research Update of 2022. The Lupus Research Alliance (LRA) made important gains on many fronts—thanks to tremendous friends like you. I hope you share my pride because your support continues to be the catalyst behind every LRA accomplishment. […] READ MORE

Encouraging Results with Obinutuzumab for Lupus Nephritis

February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY.  A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] READ MORE

Baricitinib Development as a Lupus Treatment Discontinued

January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of  OLUMIANT® (baricitinib) as a potential treatment for adults with systemic lupus erythematosus (SLE) has been discontinued. The drug’s manufacturer Lilly made this decision based on results from two Phase 3 trials (SLE-BRAVE-I and II).  While SLE-BRAVE-I showed a significant […] READ MORE

LRA-Funded Research Uncovers a Novel Pathway for Lupus Nephritis

January 28, 2022 The investigators from The Accelerated Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program, in collaboration with Drs. Chaim Putterman from the Albert Einstein College of Medicine and Chandra Mohan from the University of Houston, and the biotechnology company Equillium have discovered an immune pathway that plays an important role […] READ MORE

Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research

January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] READ MORE

Shingles Vaccine Recommended for Immunocompromised People

January, 2022 As of January, 2022, the U.S. Centers for Disease Control and Prevention (CDC) recommends the use of the vaccine Shingrix to prevent shingles and its complications in adults 19 years and older whose immune systems are weakened in addition to those adults 50 years and older whose immune systems are not compromised.  Shingrix […] READ MORE

Learn and connect with our community!